NASDAQ : KLRS
Kalaris Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 48.32M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 48.32M |
| Enterprise Value | -43.81M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 23.80M |
| Shares Outstanding | 23.80M |
| Shares Change (YoY) | +235.77% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 6.02% |
| Owned by Institutions (%) | 16.16% |
| Float | 5.90M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.98 |
| Quick Ratio | 10.70 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -79.91% |
| Return on Assets (ROA) | -31.03% |
| Return on Invested Capital (ROIC) | -53.22% |
| Return on Capital Employed (ROCE) | -52.60% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.21M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | -58.32% |
| 50-Day Moving Average | 2.95 |
| 200-Day Moving Average | 5.41 |
| Relative Strength Index (RSI) | 36.71 |
| Average Volume (20 Days) | 72,264 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 306,400 |
| Short Previous Month | 331,876 |
| Short % of Shares Out | 1.29% |
| Short % of Float | 5.20% |
| Short Ratio (days to cover) | 3.69 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -47.76M |
| Pretax Income | -44.26M |
| Net Income | -44.26M |
| EBITDA | n/a |
| EBIT | -47.76M |
| Earnings Per Share (EPS) | -$2.06 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 93.54M |
| Total Debt | 1.40M |
| Net Cash | 92.14M |
| Net Cash Per Share | $3.87 |
| Equity (Book Value) | 57.67M |
| Book Value Per Share | 2.42 |
| Working Capital | 87.18M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -41.02M |
| Capital Expenditures | -200,000 |
| Depreciation & Amortization | 33,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -41.22M |
| FCF Per Share | -$1.73 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -235.77% |
| Shareholder Yield | -235.77% |
| Earnings Yield | -101.70% |
| FCF Yield | -85.29% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.67 |
| Price Target Difference | 770.44% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |